No abstract

Intraperitoneal administration of autologous tolDCs appears safe and feasible in refractory CD patients. Further studies should be developed to test clinical benefit, determine the optimal administration route and dose, and monitor the immune responses; See [www.eudract.ema.europa.eu, EudraCT number 2007-003469-42; www.aemps.gob.es number PEI 08-049].

Development and Validation of a Simplified Magnetic Resonance Index of Activity for Crohn's disease MARIAs segment = thickening (>3mm) + edema + fat stranding + ulcers MARIAs ≥ 1 (a) activity (b) severity